KerraCel™ is a gelling fiber dressing made of 100% carboxymethyl cellulose.
• Soft, sterile, highly absorbent and conformable
• Nonwoven wound dressing made of 100% carboxymethyl cellulose (CMC)
• As wound exudates are absorbed, the CMC forms a soft gel which helps the dressing maintain a moist environment
• Supports the wound healing process
• Aids in the removal of nonviable material from the wound, without damaging newly formed tissue
KerraCel™ is indicated for the management of low to heavily exuding partial- and full-thickness chronic and acute wounds and to control minor bleeding in superficial wounds.
Under the supervision of a health care professional, KerraCel™ can be used on the following wounds including: leg ulcers, pressure ulcers (stages 2-4), diabetic ulcers, surgical wounds (e.g, post operative, wounds left to heal by secondary intent and donor sites) superficial and partial-thickness burns, cavity wounds, traumatic wounds (e.g., abrasions and lacerations) and for exudate absorption in oncology wounds (e.g., fungating cutaneous tumors, cutaneous metastases, and Kaposi's sarcomas).
The dressing can be used under compression.
KerraCel™ is not indicated for surgical implantation, to control heavy bleeding or on individuals who are sensitive to or will have an a allergic reaction to the dressing or its components.
Consult a medical professional if irritation (reddening, inflammation), maceration (whitening of skin) or hypergranulation (excess tissue formation) is observed. The dressing should be used under the supervision of a medical professional.
|Antimicrobial format available|
|Conforms readily to wound||●|
|Intact when saturated||●|
|Moisture vapor permeable||●|
|Secondary dressing required||●|
|Usable on infected wounds||●|
|Variety of sizes||●|
|Educational Material Available|
|Free Samples/Trials Available||●|
|Published Clinical Article Available|
Moderate/Highly Exudating Wounds
Non/Minimally Exudating Wounds
Acelity leverages the strengths of Kinetic Concepts and Systagenix Wound Management to provide a trusted and complementary portfolio of advanced wound therapeutics for customers and patients in more than 90 countries worldwide.